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Abstract
About 80% of patients with type 2 diabetes are classified as overweight. However, only
about 1/3 of severely obese subjects have type 2 diabetes. This indicates that several se-
verely obese individuals may possess certain characteristics that protect them against type
2 diabetes. We therefore hypothesized that this apparent paradox could be related to funda-
mental differences in skeletal muscle lipid handling. Energy metabolism and metabolic flexi-
bility were examined in human myotubes derived from severely obese subjects without
(BMI 44±7 kg/m2) and with type 2 diabetes (BMI 43±6 kg/m2). Lower insulin sensitivity was
observed in myotubes from severely obese subjects with type 2 diabetes. Lipolysis rate
was higher, and oleic acid accumulation, triacylglycerol content, and fatty acid adaptability
were lower in myotubes from severely obese subjects with type 2 diabetes compared to se-
verely obese non-diabetic subjects. There were no differences in lipid distribution and
mRNA and protein expression of the lipases HSL and ATGL, the lipase cofactor CGI-58, or
the lipid droplet proteins PLIN2 and PLIN3. Glucose and oleic acid oxidation were also simi-
lar in cells from the two groups. In conclusion, myotubes established from severely obese
donors with established type 2 diabetes had lower ability for lipid accumulation and higher li-
polysis rate than myotubes from severely obese donors without diabetes. This indicates
that a difference in intramyocellular lipid turnover might be fundamental in evolving type
2 diabetes.
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Introduction
Overweight and obesity are strongly associated with insulin resistance and type 2 diabetes, and
the majority of subjects with type 2 diabetes are classified as overweight or obese [1]. However,
a study at the Morbid Obesity Center in Norway revealed that only 31% of the severely obese
patients enrolled for screening (BMI> 35 kg/m2) had type 2 diabetes [2]. Many organs are in-
volved in obesity-related type 2 diabetes, but skeletal muscle is one of the organs where insulin
resistance is most prominent.
Skeletal muscle uses both fat and carbohydrate as fuel, and fat predominates during fasting.
Metabolic flexibility is defined as the muscle’s ability to change between predominantly fatty
acid oxidation in the fasting state and carbohydrate oxidation in the fed state (reviewed in [3]).
This flexibility is reduced in insulin resistance and type 2 diabetes in vivo [4]. Treatments that
have positive effects on muscle metabolism, such as omega-3 fatty acids, have been observed to
increase both lipid accumulation and metabolic flexibility [5]. Interestingly, it has been ob-
served that muscle cells isolated from overweight/obese patients with or without type 2 diabetes
maintain these characteristics when grown in culture [6–8]. Studies performed on cultured
skeletal muscle cells (myotubes) from severely obese subjects are few [9–13], but the main find-
ings from these studies are that myotubes from the severely obese subjects have a reduced com-
plete fatty acid oxidation compared to cells from lean subjects [10, 11, 13], in addition to a
reduced mitochondrial content [11]. Other studies on myotubes from obese subjects with dia-
betes (BMI30 kg/m2) have shown reduced lipid oxidation associated with obesity and type 2
diabetes [14–16]. This reduced oxidation in obese/diabetic muscle has been attributed to im-
paired mitochondrial capacity [17] or lower mitochondrial content [18]. There are also reports
on unaltered and/or increased fatty acid oxidation in human skeletal muscle of obese or insulin
resistant individuals [19–21]. Increased fatty acid uptake [11] and partitioning of lipids towards
storage rather than oxidation was observed in myotubes from severely obese donors compared
to lean donors [10, 11]. Skeletal muscle store fat as triacylglycerols (TAG) in lipid droplets
(LDs) and lipid droplet-binding proteins (perilipins) coat and regulate lipid droplet biogenesis
and turnover, while adipose triglyceride lipase (ATGL) and hormone sensitive lipase (HSL) are
enzymes involved in lipolysis [22–24]. Increased intramyocellular lipid storage and/or levels of
intermediates in fatty acid metabolism have been shown to correlate with decreased insulin
sensitivity (reviewed in [25]). However, insulin signaling was also improved in presence of in-
creased lipid accumulation in human myotubes [26], and treatment of myotubes with metfor-
min has been shown to increase lipid accumulation in cells from lean individuals [8]. Finally,
athletes that are highly insulin sensitive have a higher content of lipid in skeletal muscle than
both overweight sedentary and overweight type 2 diabetic individuals [27]. Based on these
findings, new theories have emerged that focus on abnormal lipid storage or TAG lipolysis
rather than lipid storage per se (reviewed in [25]).
Myotubes in culture are known to maintain many phenotypic characteristics of the donor.
We wanted to study lipid storage and turnover capacity, as well as oxidation and metabolic
flexibility of myotubes from severely obese with and without type 2 diabetes, to see whether
lipid handling is inherently different between those who develop type 2 diabetes and those who
don’t.
Materials and Methods
Materials
Dulbecco’s modified Eagles medium (DMEM-Glutamax) low glucose with sodium pyruvate,
DMEM without phenol red, heat-inactivated FCS, penicillin-streptomycin and amphotericin B
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were from Gibco Invitrogen (Gibco, Life Technologies, Paisley, UK). SkGM-bulletkit was from
Lonza (Wakersville, MD, USA). Ultroser G was from PALL (St-Germain-en-Laye, France), in-
sulin (Actrapid) from NovoNordisk (Bagsvaerd, Denmark), BSA, L-carnitine, oleic acid (OA,
18:1, n-9), and triacsin C from Sigma (St.Louis, MO, US). [1–14C]oleic acid (2.15 GBq),
[9,10-3H]triolein (37 MBq) and D-[14C-(U)]glucose (107 MBq or 185 MBq) were from Perki-
nElmer NEN (Boston, MA, US), 2-[3H] deoxy-D-glucose (370 GBq) from American Radiola-
beled Chemicals Inc. (St.Louis, MO, US). 96-well Scintiplate was from Perkin Elmer (Boston,
MA, US), Corning CellBIND tissue culture plates and flasks from Corning Life-Sciences (Schi-
phol-Rijk, The Netherlands), glass bottom 6-well plates fromMatTek (Ashland, MA, US), and
Biocoat 25cm2 cell flask from BD Biosciences (Franklin Lakes, NJ, US). MitoTrackerRed FM,
Hoechst 33258, primers for TaqMan qPCR fromMolecular Probes, Invitrogen (Carlsbad, CA,
US). RNeasy minikit was from Qiagen (Venlo, The Netherlands), SYBR green from Applied
Biosystems (Warrington, UK) and Roche Diagnostics (Mannheim, Germany). TaqMan reverse
transcription kit reagents MicroAmp Optical Reaction Plate and High-Capacity cDNA revers
transcription kit were from Applied Biosystems (Warrington, UK), Agilent Total RNA isola-
tion kit from Agilent Technologies (Santa Clara, CA, US) and TRIzol Reagent from Invitrogen
Dynal AS (Carlsbad CA, US). Immun-Star WesternC kit, Mini-Protean TGX gels were from
BioRad (Copenhagen, Denmark). SPE column was fromMacherey-Nagel (Düren, Germany).
Donor characteristics
Muscle biopsies were obtained from subjects undergoing bariatric surgery at The Morbid Obe-
sity Center at Vestfold Hospital Trust, Norway. Biopsies were obtained after informed written
consent and approval by the Regional Committee for Medical and Health Research Ethics,
Oslo, Norway (approvement S-09078d). Blood samples were taken the day before biopsy re-
trieval or earlier (range 1 month to 2 years, median 1.5 years), due to practical reasons. The di-
agnosis of type 2 diabetes was based on fasting plasma glucose7.0 mM, HbA1c 6.5% and/
or the use of one or more antidiabetic drug. Of the 14 donors in the type 2 diabetic group, 6
were on metformin monotherapy, 2 on metformin and glimepiride, 1 on metformin in combi-
nation with rosiglitazone, 1 on pioglitazone monotherapy, 2 on insulin and 2 were untreated.
The donors did not receive medication on the day of surgery.
Cell culturing
Satellite cells were isolated fromM. obliquus internus abdominis and cultured as previously de-
scribed [28]. Experiments were performed after 7–8 days of differentiation and 100 μMOA
was added the last 24h of differentiation period. Protein concentration in each sample was de-
termined [29], and the results were standardized according to this value for each well. Not all
donors were included in each set of experiment, but 5–8 donors in each group were used, and
these were carefully matched with respect to age and BMI.
Deoxyglucose uptake
Myotubes were preincubated for 1h in serum-free DMEM-Glutamax (5.5 mM glucose) ± 100
nM insulin at 37°C before addition of [3H]deoxyglucose (37 kBq, 0.1 μM) in presence or ab-
sence of 100 nM insulin. Deoxyglucose uptake was measured for 1 h as previously described
[30].
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Scintillation proximity assay
Scintillation proximity assay (SPA) was performed as previously described [31] with [1–14C]
oleic acid (OA) (18.5 kBq, 100 μM) in medium without phenol red. Briefly, [14C]OA taken up
and accumulated by adherent cells will be concentrated close to the scintillator embedded in
the plastic bottom of each well (Scintiplate, Perkin Elmer) and provide a stronger signal than
the dissolved in the medium alone [32]. Lipid accumulation was monitored up to 24h with liq-
uid scintillation. Thereafter, the cells were washed twice with DPBS with 0.5% BSA, and incu-
bated in DPBS without radioactivity and liquid scintillation measurements were monitored
up to 3h. The decline in [14C]OA present in the cells in presence of triacsin C (total lipolysis,
10 μM) [33] was determined, before the remaining cell-associated (CA) radioactivity was as-
sessed. The decline in [14C]OA represent radioactivity released by the cells and provide a mea-
sure of lipolysis. Triacsin C inhibits long-chain fatty acyl-CoA synthetase and will therefore
inhibit, among other pathways, re-esterification.
Lipid distribution
Myotubes were incubated with 100 μMOA (18.5 kBq, 100 μM) for 24 h. Myotubes were then
washed twice with PBS and harvested with two additions of 125 μl distilled water. Cellular lip-
ids were extracted as described earlier [5]. Briefly, homogenized cell fractions were extracted,
lipids were separated by thin layer chromatography, and radioactivity was quantified by liquid
scintillation. The amount of neutral lipids was related to total protein concentrations.
Determination of total TAG content
Total TAG content in the cells were measured as previously described [34]. Briefly, lipids
were extracted in dichloromethane:methanol:water (2.5:2.5:2.1 (v/v/v)) in presence of internal
standards. Neutral lipids were separated over a SPE column (glass Chromabond pure silica,
200 mg), and neutral lipids were eluted with chloroform:methanol (9:1 (v/v)). The organic
phase was evaporated to dryness and dissolved in 20 μl of ethyl acetate. 1 μl of the lipid extract
was analyzed by gas-liquid chromatography.
TAG hydrolase activity assay
TAG hydrolase activity was measured on cell lysates as previously described [35]. [9,10-3H]
triolein was emulsified with phospholipids by sonication and used to determine TAG hydrolase
activity [5].
Live imaging
Myotubes were cultured on 6-well glass bottom plates coated with ECM gel. The cells were in-
cubated with Hoechst 33258 to stain nuclei, Bodipy 493/503 to stain neutral lipids and LDs
and MitoTrackerRed FM to stain mitochondria as previously described [5]. Images were ran-
domly taken in 25–36 positions per well. After gating out aggregates and dead cells, each pa-
rameter was determined from about 240 images per donor group (average of 38±4 nuclei per
image).
Substrate oxidation assay
Myotubes were cultured on 96-well CellBIND microplates. Substrates, [1–14C]OA (18.5 or 37
kBq, 5 or 100 μM) or D-[14C(U)]glucose (37 or 21.5 kBq, 111 or 200 μM/l) were given during
4h CO2 trapping with or without 5 mM glucose or 100 μM/l OA present. A 96-well UniFilter-
96 GF/B microplate was mounted on top of the CellBIND plate and CO2 production was
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measured in DPBS medium with 10 mMHEPES and 1 mM L-carnitine for 4h, as previously
described [32]. The sum of 14CO2 and remaining CA radioactivity reflects total cell uptake. In-
complete fatty acid oxidation, assessed as acid soluble metabolites (ASMs), was measured as
described [31].
Metabolic parameters
Suppresibility is the ability of the cells to decrease OA oxidation by acutely added glucose,
adaptability is the ability to increase OA oxidation with increasing OA concentration and sub-
strate-regulated flexibility is the ability to increase OA oxidation while changing from “fed”
(low fatty acid, high glucose) to “fasted” (high fatty acid, no glucose added) condition [5].
RNA isolation and mRNA expression
Total RNA from cells was isolated by Agilent Total RNA isolation kit according to the suppli-
er’s protocol. Total RNA from muscle biopsies was isolated using TRIzol and a clean-up proce-
dure was performed using RNeasy kit. RNA was reverse-transcribed with oligo primers using a
heat block (25°C for 10 min, 37°C for 1 h and 99°C for 5 min) or a PerkinElmer Thermal Cycler
9600 and qPCR was performed using an ABI PRISMT 7000 Detection System or a LightCycler
480 (Roche Diagnostic, Mannheim, Germany). Forward and reverse primers used at concen-
tration of 30 μM are presented in S1 Table. The transcription levels were normalized to the av-
erage of housekeeping genes GAPDH and RPLP0.
Immunoblotting
Total cell lysates prepared either in Laemmli or RIPA buffer containing 10 μl/ml protease in-
hibitor, 10 μl/ml phosphatase I inhibitor and 10 μl/ml phosphatase II inhibitor were electro-
phoretically separated, blotted to nitrocellulose membrane and incubated with antibodies
recognizing human total and phosphorylated Akt (Ser473), total HSL (#4107), Ser660 HSL
(#4126) and ATGL (#2138, all from Cell Signaling Technology, Beverley, MA, US), compara-
tive gene identification 58 (CGI-58) (#H00051099-M01, Abnova, Tapei, China), PLIN2
(#PA5-25042) and PLIN3 (#PA5-20272, Thermo Scientific, France), myosin slow muscle fiber
(MAB1628, Millipore Billerica, MA, US), total OXPHOSWB antibody cocktail (#110411,
Abcam), alpha-tubulin rabbit (#2144), GAPDH (#5174) and β-actin (#4970, all from Cell Sig-
naling Technology). Immunoreactive bands were visualized with enhanced chemiluminescence
(Chemidoc XRS, BioRad) and quantified with Gel-Pro Analyzer (version 2.0) software. Anti-
bodies against GAPDH, alpha-tubulin or β-actin were used to normalize the protein-antibody
signal.
Presentation of data and statistics
Two-tailed unpaired Student’s t-tests were performed to determine the difference between the
donor groups (GraphPad Prism 5.0, GraphPad Software Inc., San Diego, CA, US). For correla-
tion studies, Spearman correlation analysis was performed and Spearman coefficient, ρ, defines
the strength of the correlation (GraphPad Prism). Linear mixed model analysis (LMM, SPSS
20.0.0.1, IBM SPSS Inc., Chicago, IL, US) was used to compare the donors in time-course fatty
acid accumulation and lipolysis experiments (SPA). Values are reported as means ±SEM if not
stated otherwise. The value n represents the number of different donors used each with at least
duplicate samples. P< 0.05 was considered statistically significant.
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Results
Cell and donor characteristics
Selected characteristics of the muscle biopsy donors are presented in Table 1. Severely obese
without type 2 diabetes and severely obese with type 2 diabetes differed in fasting plasma glu-
cose and in HbA1c. There were no differences in plasma insulin, LDL, HDL, cholesterol, or tria-
cylglycerol (data not shown). The severely obese subjects with type 2 diabetes were on average
9 years older than the severely obese subjects with normal glucose tolerance. However, the dif-
ference in age could not explain the metabolic differences between the groups, assessed by mul-
tivariate analysis, and the duration of obesity in the two groups was not statistically different.
Physical activity level (self-reported) was also similar in the two groups (data not shown). Myo-
tube cultures established from the two groups of donors revealed no difference in protein or
mRNA expression of the marker for muscle fiber type I (MYH7, slow fiber type), determined
by immunoblotting and qPCR. There were no differences in mRNA expression of myosin
heavy chains in the biopsy samples either (data not shown).
Myotubes in vitromaintain their in vivo phenotype
To confirm that the myotubes maintained their diabetic phenotype in culture, insulin-stimulat-
ed glucose uptake and Akt phosphorylation (Ser473) were measured. Insulin-stimulated phos-
phorylation of Akt tended to be lower in myotubes from severely obese donors with type 2
diabetes compared to severely obese donors with normal glucose tolerance (Fig. 1A, p = 0.11).
Insulin-stimulated glucose uptake was abolished in myotubes from type 2 diabetics compared
to cells from non-diabetics (Fig. 1B, p = 0.01), implying a conserved insulin resistance in
cultured cells.
Reduced lipid accumulation in type 2 diabetic myotubes
To evaluate lipid turnover in the cells, accumulation of oleic acid (OA), distribution of lipids
and TAG hydrolase activity were determined. Without pre-incubation with OA, there were no
differences in lipid droplet number (LD) or total neutral lipid content in myotubes from se-
verely obese donors with or without T2D (Fig. 2A, p = 0.65, p = 0.81). Cellular accumulation of
[14C]OA was significantly lower in myotubes from type 2 diabetic subjects than in myotubes
from non-diabetics (Fig. 2B, p = 0.035). TAG measured after incubation of [14C]OA for 24 h
tended to be lower in myotubes from type 2 diabetic subjects than in myotubes from non-dia-
betics (Fig. 2C, p = 0.058) with no differences in free fatty acid (FFA, p = 0.22), diacylglycerol
(DAG, p = 0.97), cholesteryl ester (CE, p = 0.59) or phospholipids (PL, p = 0.10). In line with
this, total cell content of TAGmeasured after incubation of OA for 24 h was 50% lower in myo-
tubes from type 2 diabetic subjects than in myotubes from non-diabetics (Fig. 2D, p = 0.01).
Table 1. Donor characteristics for the donor group severely obese non-diabetics (nD) and severely obese with type 2 diabetes (T2D).
Age
(yrs)
BMI (kg/
m2)
Fasting Glucose
(mmol/l)
HbA1c
(%)
Insulin
(pmol/l)
LDL
(mmol/l)
HDL
(mmol/l)
Cholesterol
(mmol/l)
TG
(mmol/l)
n Male
nD 40 ± 7 44 ± 7 5.0 ± 0.5 5.4 ± 0.5 97 ± 51 2.8 ± 0.6 1.2 ± 0.2 4.7 ± 0.8 1.6 ± 0.5 15 4
T2D 49a ±
10
43 ± 6 7.6a ± 1.5 7.1a ±
1.6
78 ± 48 2.4 ± 1.0 1.1 ± 0.3 4.4 ± 1.3 1.8 ± 0.7 14 5
Mean ± SD are presented. aSigniﬁcantly different from nD. BMI; body mass index, HbA1c; glycosylated hemoglobin, HDL; high-density lipoprotein, LDL;
low-density lipoprotein, n; number, TG; triacylglycerol.
doi:10.1371/journal.pone.0119556.t001
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Although there was no difference in TAG hydrolase (TAGH) activity (Fig. 2D, p = 0.48),
the ratio DAG/TAG tended to be higher in the myotubes from type 2 diabetic subjects (27%,
p = 0.086).
Higher lipolysis rate in type 2 diabetic myotubes
To evaluate whether increased lipolysis rate could explain the lower accumulation and cell
content of TAG in type 2 diabetic myotubes, lipolysis rate with triacsin C (total lipolysis) was
measured. Indeed, lipolysis in presence of triacsin C was significantly higher in type 2 diabetic
myotubes than in non-diabetic myotubes (Fig. 3A, p = 0.046) and total lipolysis rate related
to cell-associated OA correlated positively with fasting plasma glucose levels of the subjects
(Fig. 3B). However, there were no differences in mRNA or protein expression of the lipases
HSL and ATGL and the lipase cofactor CGI-58, or the lipid droplet proteins PLIN2 and PLIN3
between the two groups (Fig. 3C, D). The fatty acid transporter CD36 was also equally express-
ed (Fig. 3C). These genes were also measured in presence of OA, but this revealed no further
differences between the groups (data not shown). No differences were observed in biopsy sam-
ples either (S2 Table). Phosphorylation of HSL at serine 660, which is associated with activation
of the lipase, was neither different between myotubes from the two groups (Fig. 3D).
Reduced mitochondrial staining but unchanged substrate oxidation
About 40% lower mitochondrial staining, measured as MitoTrackerRed intensity, was observed
in type 2 diabetic compared to non-diabetic myotubes (Fig. 4A, B, p = 0.03). Glucose and OA
oxidation (Fig. 4C, p = 0.5, p = 0.93, respectively) were not statistically different between the
Fig 1. Decreased insulin-stimulated glucose uptake and Akt phosphorylation in myotubes from severely obese donors with type 2 diabetes. (A)
Myotubes from severely obese non-diabetic donors (nD) and severely obese donors with type 2 diabetes (T2D) were incubated for 15 min with or without 100
nM insulin, before immunoblotting analysis with antibodies against phosho-Akt (Ser473) and total-Akt were performed. Data are shown as ratio phosho-Akt/
total Akt and related to unstimulated cells (n = 4–5). Immunoblotting from one representative experiment. (B) Glucose uptake was measured by [3H]
deoxyglucose with or without 100 nM insulin for 1 h. Basal glucose uptake was 251 ± 68 nmol/mg protein (nD) and 203 ± 34 nmol/mg protein (T2D). Data are
presented as mean ± SEM normalized to unstimulated cells, n = 7–8, #p< 0.05 versus basal, *p< 0.05 versus nD.
doi:10.1371/journal.pone.0119556.g001
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groups, neither were OA and glucose uptake nor incomplete OA oxidation (ASMs) (S1 Fig.).
Further, expressions of the two OXPHOS proteins, ATP synthase unit and Complex I subunit
NDUFB8, did not differ significantly between the groups either (p = 0.058 and p = 0.14, respec-
tively, Fig. 4D, E). We were not able to detect Complex II subunit 30 kDa, Complex III subunit
Core 2 and Complex IV subunit 2 of the OXPHOS protein complex. Challenging the cells with
Fig 2. Lower lipid accumulation in myotubes from severely obese donors with type 2 diabetes. (A)
Live imaging of lipid droplets and total neutral lipid content in myotubes from severely obese non-diabetic
donors (nD) and severely obese donors with type 2 diabetes (T2D). The cells were incubated for 15 min with
Hoechst 33258 to stain nuclei and Bodipy 493/503 to stain neutral lipids, n = 5. (B) [14C]OA accumulation
over 0–24 h. n = 5–6. (C) Lipid distribution measured as incorporation of [14C]OA into TAG, FFA, DAG, CE
and PL. Data are presented as % of total lipids in the cell, n = 5. (D) Total cell content of TAG and TAG
hydrolase (TAGH) activity in non-diabetic and type 2 diabetic myotubes after 24 h incubation with 100 μMOA.
Total cell content of TAG was 1.4±0.2 nmol/mg protein (T2D) and 3.0±0.6 nmol/mg protein (nD). TAGH was
3.7±0.3 nmol mg protein−1 h−1 (T2D) and 4.1±0.8 nmol mg protein−1 h−1 (nD) Data are presented relative to
mean values of non-diabetics, n = 6–7. *p<0.05 versus non-diabetic. CE, cholesteryl ester; DAG,
diacylglycerol; FFA, free fatty acid; OA, oleic acid; PL, phospholipid; TAG, triacylglycerol.
doi:10.1371/journal.pone.0119556.g002
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the mitochondrial uncoupler FCCP (carbonyl cyanide 4-trifluoromethoxy phenylhydrazone,
1 μM) or higher OA concentrations (600 μM) revealed no further difference between groups
(data not shown). Moreover, there were no differences between the groups in mRNA expres-
sion of essential genes in energy metabolism, e.g. carnitine palmitoyltransferase 1B (CPT1B),
pyruvate dehydrogenase kinase isozyme 4 (PDK4), peroxisome proliferator-activated receptor
gamma coactivator-1 alpha (PPARGC1A) and cytochrome C-1 (CYC1) (data not shown).
Metabolic flexibility
The metabolic flexibility parameters were determined as described before [5], and myotubes
derived from type 2 diabetics showed an about 30% lower adaptability for OA oxidation than
myotubes from non-diabetics, whilst the substrate-regulated flexibility and suppressibility pa-
rameters were not significantly different (Fig. 5, p = 0.02, p = 0.26, p = 0.45, respectively).
Fig 3. Higher lipolysis rate in myotubes from severely obese donors with type 2 diabetes. (A) Total lipolysis (with triacsin C) after 24 h incubation with
[14C]OA in non-diabetic (nD) and type 2 diabetic myotubes (T2D) n = 5–6. (B) Fasting plasma glucose levels correlated positively with total lipolysis rate, n =
11 (C) mRNA expression of hormone-sensitive lipase (HSL), adipose triglyceride lipase (ATGL), perilipin 2 (PLIN2), perilipin 3 (PLIN3) and the fatty acid
transporter CD36. Data are presented relative to mean values of non-diabetics, n = 6–10. (D-E) Protein expression of HSL, ATGL, comparative gene
identification 58 (CGI-58), PLIN2 and PLIN3 and phosphorylation of HSL at serine 660 (HSL Ser660) after 24h incubation with 100 μMOA. (D) Two
representative blots are shown. Data are presented relative to mean values of non-diabetics, n = 5.
doi:10.1371/journal.pone.0119556.g003
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Fig 4. Lower mitochondrial staining of myotubes from severely obese donors with type 2 diabetes.Myotubes from severely obese non-diabetic
donors (nD) and severely obese donors with type 2 diabetes (T2D) were stained with MitoTrackerRed (mitochondria) and Hoechst 33258 (nuclei). (A)
Representative images after 24h incubation with 100 μM oleic acid (OA). Blue is nuclei and red is mitochondria. Magnification is 1:20, scale bar represents
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Discussion
Disturbances in skeletal muscle lipid metabolism are clearly associated with insulin resistance
and type 2 diabetes. In the present study, we wanted to examine lipid handling in myotubes
50 μm. (B) Mitochondrial staining related to number of nuclei per 100 0000 AU. Myotubes were incubated with or without 100 μM oleic acid (OA). Mean±SEM
are presented related to number of nuclei, n = 5, *p<0.05 versus non-diabetics. (C)OA oxidation or glucose oxidation were measured in presence of [14C]OA
(18.5 kBq, 100 μM) or [14C]glucose (18.5 kBq, 200 μM) for 4h. Data are presented as mean±SEM, n = 7. AU, arbitrary units. (D-E) Protein expressions of ATP
synthase subunit and Complex I subunit NDUFB8. Protein samples were harvested and analyzed as described in Materials and Methods, and expression
levels were normalized to alpha-tubulin. (D)Representative Western blots from one experiment. (E) Protein expressions of ATP synthase subunit and
Complex I subunit NDUFB8 related to alpha-tubulin. Data are presented as mean±SEM, n = 5–8.
doi:10.1371/journal.pone.0119556.g004
Fig 5. Metabolic flexibility parameters in myotubes derived from severely obese non-diabetic donors
(nD) and severely obese donors with type 2 diabetes (T2D). Calculations of metabolic parameters are
performed as described [5]. Suppressibility is (1- oxidation of 100 μMOA at 5 mM glucose/oxidation of
100 μMOA at no glucose added)*100%, adaptability is oxidation of 100 μMOA/oxidation of 5 μMOA, and
substrate-regulated flexibility is oxidation of 100 μMOAwithout glucose added/oxidation of 5 μMOA at 5 mM
glucose. Linear mixed model was performed for adaptability and suppressibility, while unpaired two-tailed
t-test was performed for substrate-regulated flexibility, *p<0.05 versus non-diabetics, n = 7–8.
doi:10.1371/journal.pone.0119556.g005
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isolated from severely obese that have developed type 2 diabetes and severely obese with nor-
mal glucose tolerance to see whether there are fundamental differences. We observed that myo-
tubes established from severely obese type 2 diabetic donors had higher lipolysis rate and were
less able to accumulate fatty acids than myotubes from severely obese with normal glucose tol-
erance. In line with this, TAG content was lower in myotubes from type 2 diabetic donors but
there were no significant differences in lipid distribution into FFA, DAG, CE or PL. There were
no differences in fatty acid and glucose oxidation either. Although the diabetic cells had lower
mitochondrial content as assessed by Mitotracker, expression levels of the OXPHOS proteins
did not differ significantly between the groups. Further, diabetic cells showed less ability to in-
crease fatty acid oxidation with increased oleic acid availability (adaptability). We also con-
firmed that myotubes derived from severely obese donors with T2D had lower insulin
sensitivity compared to cells from non-diabetic donors, a trait apparently conserved from the
in vivo situation.
There are numerous studies showing an association between insulin resistance and in-
creased lipid accumulation in skeletal muscle of type 2 diabetic subjects [25, 36]. However,
there are also indications that this association is not solely due to ectopic lipid accumulation,
but rather caused by dysregulation of lipolysis and/or lipid turnover [25, 27, 37]. Lower lipid
accumulation and higher lipolysis without correspondingly increased fatty acid oxidation, as
observed in type 2 diabetic myotubes in this study, could contribute to accumulation of lipo-
toxic intermediates, which are reported to interfere with insulin signaling [38–40], (reviewed in
[25]). Although we could not observe any differences in DAG content, the ratio of DAG/TAG
tended to be higher in type 2 diabetic myotubes. In correspondence with this, higher DAG
level in muscle has been associated with obesity and insulin resistance in both rats and humans
[39, 41], while muscle ceramides are also elevated in lean or obese insulin resistant humans
and rats [41]. Although TLC is a sensitive method, we cannot exclude that small differences
that we were not able to detect, in for instance DAG or other lipid intermediates could mediate
important signaling effects.
We observed lower lipid accumulation and higher lipolysis rate in myotubes from severely
obese type 2 diabetic donors without any difference between cells from the two groups with re-
spect to protein and mRNA expression levels of CD36, PLINs, ATGL, HSL and CGI-58. Re-
duced protein expression of the lipase HSL has previously been shown in obese insulin-
resistant subjects [24, 42], and increased protein levels of ATGL in both obese subjects with
type 2 diabetes [22] and obese non-diabetic subjects [24]. However, no apparent changes in li-
pases and PLIN proteins were observed in the present study despite functional changes in lipol-
ysis. The regulation of lipase activity is a complex process regulated at multiple steps, including
phosphorylation of lipases and PLIN proteins and complex movement of these different part-
ners between the lipid droplets and the cytosol [43]. HSL activity is probably mostly regulated
by phosphorylation [43]. However, we were not able to detect any differences in HSL660 phos-
phorylation in myotubes from the two donor groups, but other phosphorylation sites, not stud-
ied here, may be involved. Recently, we observed that increased expression of ATGL by
palmitic acid in myotubes, did not increase lipolysis, implying that content and activity are not
directly linked [31]. ATGL can also be phosphorylated, although its activity appears mainly
controlled by the co-activator CGI-58 [43]. Exactly how lipolysis rate is regulation by PLINs is
not known, but PLIN2 has been found co-localized with HSL after epinephrine stimulation,
and PLIN5 is suggested to channel fatty acids to the mitochondria after lipolysis [43]. In accor-
dance with a recent observation in myotubes from obese individuals with or without type 2 dia-
betes [44], we could not detect any change in expressions of PLIN2 and PLIN3, and further
investigation on how PLINs and lipases interact is needed.
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TAG content of type 2 diabetic myotubes was about 50% of the content in non-diabetic con-
trols after 24 h incubation with OA. This difference can possibly be explained by increased lipo-
lytic rate, combined with less lipid accumulation. However, there might also be differences in
TAG synthesis, for instance DGAT activity or in lipid uptake. A complete picture is difficult to
interpret. CD36 expression was similar as well as fatty acid uptake, assessed as cell associated OA
after 4 h (data not shown), and Sparks et al. showed very recently that DGAT-activity did not dif-
fer between myotubes from obese males with T2D and BMI and age matched controls [44]. Alto-
gether, we have documented disturbed lipid handling, but still the explanation is puzzling.
In addition to lipid turnover, metabolic flexibility was also impaired in myotubes derived
from type 2 diabetic donors, assessed as reduced adaptability for fatty acid oxidation. In support,
lower ability to increase oxidation with increasing fatty acid concentration in myotubes from
overweight/obese type 2 diabetics [8] and reduced metabolic flexibility in vivo in insulin resistant
muscle [4] compared to healthy lean donors have been reported. The combination of decreased
adaptability and higher lipolysis rate might be unfavorable and likely contribute to an abnormal
intracellular lipid profile. Interestingly, we found lower mitochondrial staining in myotubes from
severely obese with type 2 diabetes compared to cells from severely obese non-diabetic donors, in
accordance with earlier studies showing lower mitochondrial content in insulin resistant muscle
[17, 45]. This occurred despite no differences in fatty acid oxidation, nor in the OXPHOS protein
expression or mRNA expression of CYC1, PPARGC1A, CPT1B or PDK4 in myotubes from se-
verely obese donors with type 2 diabetes compared to cells from severely obese non-diabetic do-
nors. The focus in recent years has been directed towards a mitochondrial deficiency/dysfunction
in relation to development of type 2 diabetes, and several studies conclude that the observed re-
duced mitochondrial function in type 2 diabetes is due to, and secondary to, a lower mitochon-
drial content in muscle (reviewed in [46]). Although one might expect that oxidation and
mitochondrial content are positively associated, an inverse correlation between mitochondrial
content and degree of complete lipid oxidation has been observed in myotubes [47].
Increasing age is related to elevated insulin resistance and so is increasing obesity related to
aging. The subjects with type 2 diabetes in this study were in average older than the non-diabet-
ic subjects, however, the duration of obesity did not differ and age per se could not explain the
metabolic differences. It is also hypothesized that obesity and inactivity rather than age per se is
the primary determinant of age-related declines in insulin sensitivity [48, 49].
Altogether, our results show that there are retained differences in cells cultured from sub-
jects with and without diabetes. This is in accordance with many previous observations [6, 14,
44]. Actually, how these differences are conserved from the in vivo to the in vitro situation is
not known. Most studies have failed to explain this by genetic polymorphism, but a possibility,
yet undetected, is that epigenetic changes could accumulate in vivo and be transmitted to in the
cultured cells, causing a diabetic phenotype.
In conclusion, myotubes established from severely obese subjects with established type 2 di-
abetes had lower ability for lipid accumulation and higher lipolysis rate than myotubes from se-
verely obese donors without diabetes. Our hypothesis is that by storing more lipids as
triacylglycerol, the formation of lipotoxic intermediates that could interfere with insulin signal-
ing may be prevented. Higher lipolysis not followed by a higher fatty acid oxidation, in combi-
nation with lower adaptability and lower mitochondrial content could contribute to a diabetic
metabolic profile.
Supporting Information
S1 Fig. Oleic acid and glucose uptake and acid soluble metabolites (ASM) in myotubes de-
rived from severely obese non-diabetics (nD) and severely obese diabetics (T2D). (A)
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Cellular uptake of oleic acid and glucose, assessed as the sum of cell associated and CO2-
trapped radioactivity after 4 h, n = 7. (B) Incomplete fatty acid oxidation, detected as ASM,
were assessed after incubation of 100 μM or 600 μM oleic acid (OA) for 24 h, n = 5. Data are
presented as mean ± SEM.
(TIF)
S1 Table. Primer sequences used in real time RT-PCR.
(PDF)
S2 Table. mRNA expression in biopsies for the donor groups severely obese non-diabetics
(nD) and severely obese with type 2 diabetes (T2D). Data are presented as fold change to the
average of two housekeeping genes (GAPDH and RPLP0). Mean ± SEM are presented for n = 7
donors per group.
(PDF)
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